Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial

Justin B McKee, John Elston, Nikos Evangelou, Stephen Gerry, Lars Fugger, Christopher Kennard, Yazhuo Kong, Jacqueline Palace, Matthew Craner, Justin B McKee, John Elston, Nikos Evangelou, Stephen Gerry, Lars Fugger, Christopher Kennard, Yazhuo Kong, Jacqueline Palace, Matthew Craner

Abstract

Introduction: Neurodegeneration is a widely accepted contributor to the development of long-term disability in multiple sclerosis (MS). While current therapies in MS predominantly target inflammation and reduce relapse rate they have been less effective at preventing long-term disability. The identification and evaluation of effective neuroprotective therapies within a trial paradigm are key unmet needs. Emerging evidence supports amiloride, a licenced diuretic, as a neuroprotective agent in MS through acid sensing ion channel blockade. Optic neuritis (ON) is a common manifestation of MS with correlates of inflammation and neurodegeneration measurable within the visual pathways. Amiloride Clinical Trial In Optic Neuritis (ACTION) will utilise a multimodal approach to assess the neuroprotective efficacy of amiloride in acute ON.

Methods and analysis: 46 patients will be recruited within 28 days from onset of ON visual symptoms and randomised on a 1:1 basis to placebo or amiloride 10 mg daily. Double-blinded treatment groups will be balanced for age, sex and visual loss severity by a random-deterministic minimisation algorithm. The primary objective is to demonstrate that amiloride is neuroprotective in ON as assessed by scanning laser polarimetry of the peripapillary retinal nerve fibre layer (RNFL) thickness at 6 months in the affected eye compared to the unaffected eye at baseline. RNFL in combination with further retinal measures will also be assessed by optical coherence tomography. Secondary outcome measures on brain MRI will include cortical volume, diffusion-weighted imaging, resting state functional MRI, MR spectroscopy and magnetisation transfer ratio. In addition, high and low contrast visual acuity, visual fields, colour vision and electrophysiology will be assessed alongside quality of life measures.

Ethics and dissemination: Ethical approval was given by the south central Oxford B research ethics committee (REC reference: 13/SC/0022). The findings from ACTION will be disseminated through peer-reviewed publications and at scientific conferences.

Trial registration number: EudraCT2012-004980-39, ClinicalTrials.gov Identifier: NCT01802489.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Amiloride Clinical Trial In Optic Neuritis (ACTION) trial visit schedule. Aq-4, aqusporin-4; FBC, full-blood count; HVF, Humphrey visual field; LCVA, low contrast visual acuity; LFT, liver function test; GDx, scanning laser polarimetry; OCT, optical coherence tomography; PERG, pattern electroretinogram; PVEP, pattern visually evoked potential; QOL, quality of life; VA, visual acuity; VEP, visual evoked potential.
Figure 2
Figure 2
Amiloride Clinical Trial In Optic Neuritis (ACTION) trial inclusion and exclusion criteria. EDSS, Expanded Disability Status Scale; eGFR, estimated-glomerular filtration rate; ON, optic neuritis.

References

    1. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999;12:295–302. 10.1097/00019052-199906000-00008
    1. Pau D, Al Zubidi N, Yalamanchili S et al. . Optic neuritis. Eye (Lond) 2011;25:833–42. 10.1038/eye.2011.81
    1. Beck RW, Gal RL, Bhatti MT et al. . Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 2004;137:77–83. 10.1016/S0002-9394(03)00862-6
    1. Sisto D, Trojano M, Vetrugno M et al. . Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. Invest Ophthalmol Vis Sci 2005;46:1264–8. 10.1167/iovs.03-1213
    1. Toussaint D, Perier O, Verstappen A et al. . Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis. J Clin Neuroophthalmol 1983;3:211–20.
    1. Kerrison JB, Flynn T, Green WR. Retinal pathologic changes in multiple sclerosis. Retina 1994;14:445–51. 10.1097/00006982-199414050-00010
    1. Suhs KW, Hein K, Sattler MB et al. . A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 2012;72:199–210. 10.1002/ana.23573
    1. Syc SB, Saidha S, Newsome SD et al. . Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain 2012;135(Pt 2):521–33. 10.1093/brain/awr264
    1. Trip SA, Schlottmann PG, Jones SJ et al. . Scanning laser polarimetry quantification of retinal nerve fiber layer thinning following optic neuritis. J Neuroophthalmol 2010;30:235–42. 10.1097/WNO.0b013e3181dbfeac
    1. Henderson AP, Altmann DR, Trip AS et al. . A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010;133:2592–602. 10.1093/brain/awq146
    1. Petzold A, de Boer JF, Schippling S et al. . Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010;9:921–32. 10.1016/S1474-4422(10)70168-X
    1. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005;233:3–13. 10.1016/j.jns.2005.03.031
    1. Vergo S, Craner MJ, Etzensperger R et al. . Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain 2011;134(Pt 2):571–84. 10.1093/brain/awq337
    1. Friese MA, Craner MJ, Etzensperger R et al. . Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med 2007;13:1483–9. 10.1038/nm1668
    1. Arun T, Tomassini V, Sbardella E et al. . Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride. Brain 2013;136(Pt 1):106–15. 10.1093/brain/aws325
    1. Naismith RT, Tutlam NT, Xu J et al. . Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology 2009;73:46–52. 10.1212/WNL.0b013e3181aaea32
    1. Frohman EM, Dwyer MG, Frohman T et al. . Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci 2009;282:96–105. 10.1016/j.jns.2009.04.010
    1. Kupersmith MJ, Mandel G, Anderson S et al. . Baseline, one and three month changes in the peripapillary retinal nerve fiber layer in acute optic neuritis: relation to baseline vision and MRI. J Neurol Sci 2011;308:117–23. 10.1016/j.jns.2011.05.039
    1. Tewarie P, Balk L, Costello F et al. . The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE 2012;7:e34823 10.1371/journal.pone.0034823
    1. Saidha S, Syc SB, Durbin MK et al. . Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler 2011;17:1449–63. 10.1177/1352458511418630
    1. Dasenbrock HH, Smith SA, Ozturk A et al. . Diffusion tensor imaging of the optic tracts in multiple sclerosis: association with retinal thinning and visual disability. J Neuroimaging 2011;21:e41–9. 10.1111/j.1552-6569.2010.00468.x
    1. Ciccarelli O, Toosy AT, Hickman SJ et al. . Optic radiation changes after optic neuritis detected by tractography-based group mapping. Hum Brain Mapp 2005;25:308–16. 10.1002/hbm.20101
    1. De Stefano N, Narayanan S, Francis GS et al. . Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65–70. 10.1001/archneur.58.1.65
    1. Wattjes MP, Harzheim M, Lutterbey GG et al. . High field MR imaging and 1H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis: correlation between metabolic alterations and diagnostic MR imaging criteria. J Neurol 2008;255:56–63. 10.1007/s00415-007-0666-9
    1. Wang K, Jiang T, Yu C et al. . Spontaneous activity associated with primary visual cortex: a resting-state FMRI study. Cerebral Cortex 2008;18:697–704. 10.1093/cercor/bhm105
    1. Gallo A, Esposito F, Sacco R et al. . Visual resting-state network in relapsing-remitting MS with and without previous optic neuritis. Neurology 2012;79:1458–65. 10.1212/WNL.0b013e31826d5eea
    1. Audoin B, Fernando KT, Swanton JK et al. . Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. Brain 2006;129(Pt 4):1031–9. 10.1093/brain/awl039
    1. Schmierer K, Scaravilli F, Altmann DR et al. . Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56:407–15. 10.1002/ana.20202
    1. Henderson AP, Altmann DR, Trip SA et al. . Early factors associated with axonal loss after optic neuritis. Ann Neurol 2011;70:955–63. 10.1002/ana.22554
    1. Brusa A, Jones SJ, Plant GT. Long-term remyelination after optic neuritis: a 2-year visual evoked potential and psychophysical serial study. Brain 2001;124:468–79. 10.1093/brain/124.3.468
    1. Holder GE. The incidence of abnormal pattern electroretinography in optic nerve demyelination. Electroencephalogr Clin Neurophysiol 1991;78:18–26. 10.1016/0013-4694(91)90014-U
    1. Fraser CL, Holder GE. Electroretinogram findings in unilateral optic neuritis. Doc Ophthalmol 2011;123:173–8. 10.1007/s10633-011-9294-x
    1. Sakai RE, Feller DJ, Galetta KM et al. . Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol 2011;31:362–73. 10.1097/WNO.0b013e318238937f
    1. Walter SD, Ishikawa H, Galetta KM et al. . Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology 2012;119:1250–7. 10.1016/j.ophtha.2011.11.032
    1. Costello F, Hodge W, Pan YI et al. . Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Mult Scler 2008;14:893–905. 10.1177/1352458508091367
    1. Hickman SJ, Ko M, Chaudhry F et al. . Optic neuritis: an update typical and atypical optic neuritis. Neuroophthalmology 2008;32:237–48. 10.1080/01658100802391905
    1. Hickman SJ, Dalton CM, Miller DH et al. . Management of acute optic neuritis. Lancet 2002;360:1953–62. 10.1016/S0140-6736(02)11919-2
    1. Wakakura M, Minei-Higa R, Oono S et al. . Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol 1999;43:127–32. 10.1016/S0021-5155(98)00072-0
    1. Storoni M, Pittock SJ, Weinshenker BG et al. . Optic neuritis in an ethnically diverse population: higher risk of atypical cases in patients of African or African-Caribbean heritage. J Neurol Sci 2012;312:21–5. 10.1016/j.jns.2011.08.030
    1. Xiong Z, Zhu X, Chu X et al. . Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell 2004;118:687–98. 10.1016/j.cell.2004.08.026
    1. Jenkinson M, Beckmann CF, Behrens TE et al. . FSL. Neuroimage 2012;62:782–90. 10.1016/j.neuroimage.2011.09.015

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever